Ontology-based representation and analysis of conditional vaccine immune responses using Omics data







Anthony Huffman, Tim Brunson, Nasim Sanati, Jie Zheng, Anna Maria Masci, Guanming Wu, Yongqun He 8/31/23

ImmPort database

- ImmPort is NIH-supported Immunology data portal
 - <u>https://www.immport.org/</u>
- Combines data from many sources:
 - Centers of Excellence for Influenza Research and Surveillance (CEIRS)
 - Human Immunology Project Consortium (HIPC)
- Variety of complete clinical and mechanistic studies
 - By assay, and focus
- Datasets are heterogeneous but can be used for pathway analysis



Reactome Pathway Analysis of Female Immune Response to Flu Vaccines




VaximmutorDB and Ontology Standardization

VaximmutorDB

- \odot Web-based database focused on vaccine immune effectors ('vaximmutor')
- o Vaccines are processed material used to generate immune memory
- \odot 1700+ experimentally identified vaximmutors
 - E.g. IFN-gamma, IL-2, II-4, IL-6
- \odot Pathway analysis focused on 4 yellow fever and influenza vaccines
- Analysis of multiple vaccines hard due to heterogeneity
- Standardization of pathway expression can be done through ontology
 Ovaccine Ontology (VO) for vaccine representation
 Ovaccine Investigation Ontology (VIO) for research of vaccine studies
 - \odot Vaccine Investigation Ontology (VIO) for research of vaccine studies

Study Workflow



Pathway Enrichment Analysis

- Selection of influenza vaccines done via VIGET Web Tool
 - Vaccine Induced Gene Expression analysis Tool
- Expression time points were based on Day 0 to Days 3, 7, 14
 - Ó Day 0 is váccine administration date
- Gene list determined by following criteria expression:
 - o If magnitude change greater than threshold
 - o If p-value < 0.05
- Pathway determined significant if adjusted FDR < 0.05





Figure 1 from Bunson et al 2023. Selection of analysis options utilized for VIGET. Analysis utilized the same adjustments.

Vaccine response Omics data analysis using ontology-annotated ImmPort and GEO.



Standardization of ImmPort Exposure Metadata

| Α | | | | | | \frown | | | | | | | | |
|----------|---|--|--|---|--|---|--|--|--|--|--|--|--|--|
| | В | | C \ | D | E | F | | | | | | | | |
| | | / | | EXPOSURE | EXPOSURE | | | | | | | | | |
| KPOSURE_ | ARM_ | | EXPOSURE_ | _MATERIAL | _PROCESS | SUBJECT | | | | | | | | |
| CCESSION | ACCESSION | | MATERIAL_ID | _REPORTED | _REPORTED | _ACCESSION | | | | | | | | |
| 48058 | ARM5757 | | VO_000867 | Influvac | vaccination | SUB233686 | | | | | | | | |
| 48059 | ARM5757 | | VO_000867 | Influvac | vaccination | SUB233687 | | | | | | | | |
| 48060 | ARM5757 | | VO_000867 | Influvac | vaccination | SUB233688 | | | | | | | | |
| 48061 | ARM5757 | | VO_000867 | Influvac | vaccination | SUB233689 | | | | | | | | |
| 48062 | ARM5757 | | VO_000867 | Influvac | vaccination | SUB233690 | | | | | | | | |
| 48063 | ARM5757 | | VO_000867 | Influvac | vaccination | SUB233691 | | | | | | | | |
| 48064 | ARM5757 | | VO_000867 | Influvac | vaccination | SUB233692 | | | | | | | | |
| 48065 | ARM5757 | | VO_000867 | Influvac | vaccination | SUB233693 | | | | | | | | |
| 48066 | ARM5757 | | VO_000867 | Influvac | vaccination | SUB233694 | | | | | | | | |
| 48067 | ARM5757 | | VO_000867 | Influvac | vaccination | SUB233695 | | | | | | | | |
| 22967 | ARM5032 | | VO_0000644 | HBV Vaccine | vaccination | SUB209984 | | | | | | | | |
| 22969 | ARM5033 | | VO_0000644 | HBV Vaccine | vaccination | SUB209985 | | | | | | | | |
| 22971 | ARM5032 | | VO_0000644 | HBV Vaccine | vaccination | SUB209986 | | | | | | | | |
| 22973 | ARM5028 | | VO_000644 | HBV Vaccine | vaccination | SUB209987 | | | | | | | | |
| | CESSION 48058 48059 48060 48061 48062 48063 48063 48064 48065 48066 48066 48067 22967 22967 22969 22971 | CESSION ACCESSION 48058 ARM5757 48059 ARM5757 48060 ARM5757 48061 ARM5757 48062 ARM5757 48063 ARM5757 48064 ARM5757 48065 ARM5757 48066 ARM5757 48067 ARM5757 22967 ARM5032 22971 ARM5032 | CESSION ACCESSION 48058 ARM5757 48059 ARM5757 48060 ARM5757 48061 ARM5757 48062 ARM5757 48063 ARM5757 48064 ARM5757 48065 ARM5757 48066 ARM5757 48067 ARM5757 22967 ARM5032 22971 ARM5032 | CESSION ACCESSION MATERIAL_ID 48058 ARM5757 VO_0000867 48059 ARM5757 VO_0000867 48060 ARM5757 VO_0000867 48061 ARM5757 VO_0000867 48062 ARM5757 VO_0000867 48063 ARM5757 VO_0000867 48064 ARM5757 VO_0000867 48065 ARM5757 VO_0000867 48066 ARM5757 VO_0000867 48066 ARM5757 VO_0000867 48067 ARM5757 VO_0000867 48067 ARM5757 VO_0000867 22967 ARM5032 VO_0000644 22969 ARM5033 VO_0000644 22971 ARM5032 VO_0000644 | CPOSURE_ CCESSIONARM_ ACCESSIONEXPOSURE_ MATERIAL_IDMATERIAL REPORTED48058ARM5757VO_0000867Influvac48059ARM5757VO_0000867Influvac48060ARM5757VO_0000867Influvac48061ARM5757VO_0000867Influvac48062ARM5757VO_0000867Influvac48063ARM5757VO_0000867Influvac48064ARM5757VO_0000867Influvac48065ARM5757VO_0000867Influvac48066ARM5757VO_0000867Influvac48067ARM5757VO_0000867Influvac48067ARM5757VO_0000867Influvac22967ARM5032VO_0000644HBV Vaccine22969ARM5033VO_0000644HBV Vaccine22971ARM5032VO_0000644HBV Vaccine | CPOSURE_ CCESSIONARM_ ACCESSIONEXPOSURE_ MATERIAL_IDMATERIAL _REPORTEDPROCESS _REPORTED48058ARM5757VO_0000867Influvacvaccination48059ARM5757VO_0000867Influvacvaccination48060ARM5757VO_0000867Influvacvaccination48061ARM5757VO_0000867Influvacvaccination48062ARM5757VO_0000867Influvacvaccination48063ARM5757VO_0000867Influvacvaccination48064ARM5757VO_0000867Influvacvaccination48065ARM5757VO_0000867Influvacvaccination48066ARM5757VO_0000867Influvacvaccination48067ARM5757VO_0000867Influvacvaccination48067ARM5757VO_0000867Influvacvaccination22967ARM5032VO_0000644HBV Vaccinevaccination22971ARM5032VO_0000644HBV Vaccinevaccination | | | | | | | | |



VO IDs

Statistics of ImmPort Metadata Studies

- Statistics from on February 28, 2023
 - o Earlier model used for analysis back in 2020
- 36,140 immune records
- 6,258 vaccine-related immune exposure records
- 4,607 human subjects
- 324 cohorts for each study
- 37 listed vaccines

Ontological representation of 37 vaccines in Immport



Use Case 1: Ontology-based query of vaccines and vaccine investigation data

- VO hierarchy easily identifies differences between vaccine targets
 - Can search by clade or species
 - Can be utilized by SPARQL or DL Queries
- VO axioms can identify additional types of vaccines
 - 'live attenuated vaccine' 'has quality' some 'vaccine organism live attenuated'
 - 'inactivated vaccine' 'has quality' some 'vaccine organism inactivated'
- VO terms extracted for VIGET to support queries and analysis
 - JSON file contain simplified hierarchy using this format

Use Case 2: Detecting the effect of biological sex on gene expression profiles stimulated by influenza vaccine


- Males and females have differing immune response
 - Immune response to viruses can affect either harder
- Can VIGET identify these patterns for influenza vaccines
 - Already done in original paper for yellow fever vaccines
- Utilized 16 Studies for 6 influenza vaccines
 - FluMist (VO_000044) live attenuated
 - Fluarix (VO_000045), Fluzone (VO_000047), Fluvirin (VO_000046), the 2008-2009 trivalent inactivated vaccine (VO_0004808) and the 2011-2012 trivalent inactivated vaccine (VO_0004810) - inactivated
- Analysis covered paired expression data
 - 210 males and 260 females from smallest pairing

Differential gene expression summary


- Day 7 is peak for number of differential genes expressed
- Females have greater differential response for genes than males
- Males lag behind females for significant number of pathways

| | Fold Change | # of Significant Flu | # of Significant Flu | # of Significant Flu F | # of Significant Flu F |
|-----------------|-------------------------------|----------------------|----------------------|------------------------|------------------------|
| Time Comparison | Threshold (Log ₂) | M Genes | M Pathways | Genes | Pathways |
| Day 3 | 0.1 | 176 | 17 | 969 | 73 |
| | 0.2 | 3 | 35 | 56 | 126 |
| | 0.3 | 0 | 0 | 9 | 126 |
| | 0.5 | 0 | 0 | 0 | 0 |
| Day 7 | 0.1 | 1388 | 0 | 1427 | 0 |
| | 0.2 | 1329 | 0 | 1052 | 3 |
| | 0.3 | 1133 | 0 | 1048 | 0 |
| | 0.5 | 1119 | 0 | 690 | 8 |
| | 1 | 626 | 2 | 515 | 10 |
| Day 14 | 0.1 | 446 | 39 | 969 | 73 |
| | 0.2 | 44 | 36 | 98 | 70 |
| | 0.3 | 4 | 68 | 11 | 34 |
| | 0.5 | 0 | 0 | 0 | (|


Table 1. Summary of gender differences in number significant genes and pathways in influenza vaccineresponse. Color indicates that males (M) or females (F) have more significant genes or pathways at eachcomparison.




(A) Flu vaccines, Females, Day 3 over Day 0




(C) Flu vaccines, Females, Day 7 over Day 0




(E) Flu vaccines, Females, Day 14 over Day 0



(B) Flu vaccines, Males, Day 3 over Day 0



(D) Flu vaccines, Males, Day 7 over Day 0



(F) Flu vaccines, Males, Day 14 over Day 0

Day 7 Immune Pathway Highlights

- Males had 2 significant immune pathways
 - 'neutrophil degranulation' (FDR = 6.48 e-7)
 - 'innate immune system' (FDR = 1.02e-2)
- Females had 10 significant pathways
 - 'neutrophil degranulation' (FDR = 5.06 e-11)
 - 'IL-4 and IL-13 signaling' (FDR = 2.31e-5)
 - 'IL-10 signaling' (FDR = 4.01e-2)
 - 'CLEC7A/inflammasome pathway' (FDR = 4.77e-2)
- Females also found 'cell response to stress' (FDR = 3.19e-4)
 - All genes were found to be up-expressed

Sex and vaccine role cross-section analysis

- Analysis of immune response for four combinations:
 - Male live attenuated flu vaccine
 - Female live attenuated flu vaccine
 - Male inactivated influenza vaccine
 - Female inactivated influenza vaccine
- Live attenuated vaccine comparison restricted due to small data size
 - Could not run Day 0 to 3 female live attenuated influenza vaccine analysis
- Inactivated vaccines show differences in pathways at Day 14.
 - Both had reduced power due to smaller data size
 - Females: 'innate immunity' (FDR = 4.0e-2), 'programmed cellular death' (FDR = 2.13e-3)
 - Males: 'immune system' (FDR = 2.0e-2), 'interferon alpha/beta signaling' (FDR = 3.2e-2)

Applications of Ontologies to ImmPort Studies

- Ontology successfully used to guide analysis of ImmPort
 - VIGET for sex differences for influenza and yellow fever vaccines
- Process for mapping ImmPort had initial difficulties
 - Day 0 Definition Inconsistency: Of study or vaccination
 - Many tables for data not well-explained, but well annotated.
- Can be applied to other ImmPort studies
 - Analyze studies for differences in procedures or patient phenotypes
 - Age hard to analyze as it is stored by cohort and not individual

Effect of Biological Sex on Vaccine Immune Response for ImmPort Influenza Vaccines

- Males have delayed differential gene expression vaccines
- Female immune response shows stronger cellular response to stress
 - Females also had earlier pattern of neutrophil degranulation
 - Exocytosis of secretory granules for proteases and inflammatory mediators
 - Neutrophil degranulation linked to inflammatory disorders
 - Apoptosis linked to cellular stress
- Uncertain if innate effect for females or issue with safety or formulation

Acknowledgements

- Funding:
 - NIH grant 1UH2AI132931
 - Michigan Medicine Peking University Health Sciences Center Joint Institute for Clinical and Translation Research




Thank you!



Bonus Slides

Flowchart of the workflow on collecting

vaccination metadata from ImmPort and manual checking and annotation.



The eXtensible ontology development (XOD)

- 4 XOD principles:
 - XOD 1: Ontology Term Reuse
 XOD 2: Ontology Semantic Alignment
 XOD 3: Ontology
 - Design Pattern (ODP) for Term Generation & Editing
 - XOD 4: Community Extensibility

Align semantic Term(s) exists in existing ontology? ontologies (e.g., BFO, OBI, framework (XOD 2) Repeat IAO, ...) (XOD 1) no Term reuse (XOD 1) New ontology initiated: A single **ODP** applicable? and Semantic ontology format including subsets of alignment (XOD 2) existing ontologies aligned in a semantic framework yes no how? **ODP-based term** Align and add term to Add more terms and generation (XOD 3) ontology (XOD 2) semantics in the new ontology

 XOD supports interoperability

 Aim: Use XOD to update CIDO by incorporating new hostcoronavirus interaction knowledge from COVID-19 publications available in ImmPort

Ref: He Y, Xiang Z, Zheng J, Lin Y, Overton JA, Ong E. The eXtensible ontology development (XOD) principles and tool implementation to support ontology interoperability. *J Biomed Semantics*. 2018 Jan 12;9(1):3.

Reuse terms from top level